U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H25NO2
Molecular Weight 263.3752
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of O-DESMETHYLVENLAFAXINE, (+)-

SMILES

CN(C)C[C@H](C1=CC=C(O)C=C1)C2(O)CCCCC2

InChI

InChIKey=KYYIDSXMWOZKMP-OAHLLOKOSA-N
InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3/t15-/m1/s1

HIDE SMILES / InChI

Molecular Formula C16H25NO2
Molecular Weight 263.3752
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1500.0 nM [IC50]
17.0 nM [IC50]
PubMed

PubMed

TitleDatePubMed
Antidepressant prescribing by specialty and treatment of premenstrual dysphoric disorder.
2008 Dec
Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo.
2009
Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.
2009 Dec
Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis.
2009 Dec 31
Duloxetine for the management of fibromyalgia syndrome.
2009 Jul 21
Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
2009 Jun
Use of antidepressants for management of hot flashes.
2009 Nov
Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder.
2009 Nov
Undertreatment of menopausal symptoms and novel options for comprehensive management.
2009 Nov
Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.
2009 Oct
[Non-hormonal treatment for vasomotor symptoms during menopause: role of desvenlafaxine].
2009 Oct
Desvenlafaxine: application withdrawal. Desvenlafaxine: withdrawal of marketing application for depression also.
2009 Oct
Desvenlafaxine.
2009 Oct-Dec
Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials.
2010
Desvenlafaxine and weight change in major depressive disorder.
2010
Chronic thromboembolic pulmonary hypertension.
2010 Apr
The emerging modern face of mood disorders: a didactic editorial with a detailed presentation of data and definitions.
2010 Apr 12
Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
2010 Aug
Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine.
2010 Aug
Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients.
2010 Aug 1
Optimal management of perimenopausal depression.
2010 Aug 9
Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions.
2010 Aug 9
Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.
2010 Dec
Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression.
2010 Dec
Managing menopausal symptoms and depression in tamoxifen users: implications of drug and medicinal interactions.
2010 Dec
Can depression be a menopause-associated risk?
2010 Dec 1
Prescription drugs associated with reports of violence towards others.
2010 Dec 15
A comparative study on the effects of Hypericum Perforatum and passion flower on the menopausal symptoms of women referring to Isfahan city health care centers.
2010 Fall
Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial.
2010 Feb
What can be done about hot flushes after treatment for breast cancer?
2010 Feb
Correction of venlafaxine- and duloxetine-induced transaminase elevations with desvenlafaxine in a patient with Gilbert's syndrome.
2010 Jan
Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms.
2010 Jan
Mania possibly induced by desvenlafaxine.
2010 Jan
Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
2010 Jan
Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder.
2010 Jul
Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder.
2010 Jun
Update on antithrombotic therapy for stroke prevention in atrial fibrillation.
2010 Jun
Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy.
2010 Jun 15
Pharmaceutical treatment of acute bipolar depression.
2010 Jun 23
Analysis of the effect of desvenlafaxine on anxiety symptoms associated with major depressive disorder: pooled data from 9 short-term, double-blind, placebo-controlled trials.
2010 Mar
Desvenlafaxine: a therapeutic option for treatment of menopausal hot flashes.
2010 May
HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder.
2010 Nov
Gene expression profile analysis of genes in rat hippocampus from antidepressant treated rats using DNA microarray.
2010 Nov 30
Desvenlafaxine as a possible cause of acquired hemophilia.
2010 Nov-Dec
Nonhormonal management of hot flashes for women on risk reduction therapy.
2010 Oct
[Brazilian guidelines for the treatment of narcolepsy].
2010 Sep
Getting the balance right: Established and emerging therapies for major depressive disorders.
2010 Sep 7
Milnacipran: a unique antidepressant?
2010 Sep 7
Actual status of veralipride use.
2010 Sep 7
Patents
Substance Class Chemical
Created
by admin
on Thu Jul 06 07:52:11 UTC 2023
Edited
by admin
on Thu Jul 06 07:52:11 UTC 2023
Record UNII
189BFR45S0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
O-DESMETHYLVENLAFAXINE, (+)-
Common Name English
PHENOL, 4-(2-(DIMETHYLAMINO)-1-(1-HYDROXYCYCLOHEXYL)ETHYL)-, (S)-
Common Name English
(+)-O-DESMETHYLVENLAFAXINE
Common Name English
(+)-DESVENLAFAXINE
Common Name English
PHENOL, 4-((1S)-2-(DIMETHYLAMINO)-1-(1-HYDROXYCYCLOHEXYL)ETHYL)-
Systematic Name English
(S)-(+)-O-DESMETHYLVENLAFAXINE
Common Name English
Code System Code Type Description
PUBCHEM
9816723
Created by admin on Thu Jul 06 07:52:11 UTC 2023 , Edited by admin on Thu Jul 06 07:52:11 UTC 2023
PRIMARY
CAS
142761-12-4
Created by admin on Thu Jul 06 07:52:11 UTC 2023 , Edited by admin on Thu Jul 06 07:52:11 UTC 2023
PRIMARY
FDA UNII
189BFR45S0
Created by admin on Thu Jul 06 07:52:11 UTC 2023 , Edited by admin on Thu Jul 06 07:52:11 UTC 2023
PRIMARY
CAS
273749-38-5
Created by admin on Thu Jul 06 07:52:11 UTC 2023 , Edited by admin on Thu Jul 06 07:52:11 UTC 2023
SUPERSEDED
Related Record Type Details
RACEMATE -> ENANTIOMER